Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 6/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13215168 | 0.85 | KMT2A (0.51) | KDM4EMEN1ALDH1A1KMT2ATNF | |
| SCHEMBL7679910 | 0.83 | ALDH1A1 (0.59) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5843043 | 0.81 | POLB (0.54) | KMT2ABRD4NPC1 | |
| SCHEMBL6317669 | 0.81 | PTPN1 (0.48) | ALDH1A1TNFBRD4PTPN1 | |
| SCHEMBL13215164 | 0.80 | TNF (0.51) | KDM4EMEN1ALDH1A1KMT2ATNF | |
| SCHEMBL8886451 | 0.80 | ALDH1A1 (0.50) | KDM4EMEN1ALDH1A1KMT2ATNF | |
| SCHEMBL5842125 | 0.80 | ALDH1A1 (0.52) | KDM4EMEN1ALDH1A1KMT2ATNF | |
| SCHEMBL6599701 | 0.80 | BRD4 (0.52) | ALDH1A1TNFBRD4PTPN1PDE4A | |
| SCHEMBL4389091 | 0.80 | BRD4 (0.53) | BRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL2654870 | 0.79 | PTPN1 (0.55) | ALDH1A1TNFBRD4PTPN1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| EP-2994460-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | Indiana University Research and Technology Corporation (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| WO-2014182695-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-11-13 | — | — | WO | disclosed |
| US-6992085-B2 | Octahydro-2H-pyrido[1,2-a]pyrazine compounds | LES LABORATORIES SERVIER (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | KDM4E 3772/4885MEN1 2818/4885ALDH1A1 1077/4885 |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | CYP2W1, OXER1, IL1R1 | KDM4E 4530/4885MEN1 3131/4885ALDH1A1 429/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | KDM4E 3772/4885MEN1 2818/4885ALDH1A1 1077/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | KDM4E 3772/4885MEN1 2818/4885ALDH1A1 1077/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | KDM4E 3772/4885MEN1 2818/4885ALDH1A1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.